# US 7,781,208 B2 · Methods and means for targeted gene delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,781,208 B2
- Document ID: US7781208B2
- Status: Granted
- Kind: B2
- Application number: 11/348,661
- Filed: 2006-02-07
- Published: 2006-06-22
- Granted: 2010-08-24
- Earliest claimed: 1995-07-25
- Assignees: Crucell Holland B.V.
- Inventors: Domenico Valerio; Victor W. Van Beusechem
- Web page: https://patentgrep.com/patent/US7781208B2

## CPC

- C07K 14/005: from viruses
- A61K 47/6898: {using avidin- or biotin-conjugated antibodies}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C12N 2710/00088: for redistribution
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/13045: Special targeting system for viral vectors
- C12N 2740/13052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2810/855: from receptors; from cell surface antigens; from cell surface determinants
- C12N 2810/859: from immunoglobulins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is not directly associated with the surface of the target cell. These vehicles can be rendered unable to bind to their natural cell receptor. The targeting conjugates include the counterpart member of the specific binding pair, linked to a targeting moiety which is a cell-type specific ligand (or fragments thereof). The number of the specific binding pair present on the viral vehicles can be, for example, an immunoglobulin binding moiety (e.g., capable of binding to a Fc fragment, protein A, protein G, FcR or an anti-Ig antibody), or biotin, avidin or streptavidin. The virus' outer membrane or capsid may contain a substance which mediates entrance of the gene delivery vehicle into the target cell. Due to the specificity of the ligand, the binding pair's high affinity, and the gene delivery vehicle's inability to be targeted when used alone, the universality of the method for gene delivery, together with its high cell type selectively can be achieved by using various targeting conjugates.

## Claims

### Claim 1

A targeting gene delivery vehicle complex, said targeting gene delivery vehicle complex comprising:
a gene delivery vehicle coupled to a bispecific conjugate;
wherein said gene delivery vehicle comprises
a retrovirus comprising an expressible nucleic acid molecule encoding a recombinant gene of interest; and
a first member of a specific binding pair, wherein said first member of the specific binding pair is recombinantly expressed on the exterior of the retrovirus; and
wherein said bispecific conjugate comprises a second member of said specific binding pair covalently coupled to a targeting moiety capable of binding to a target molecule associated with the surface of a target cell.

### Claim 2 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the first member of a specific binding pair comprises an immunoglobulin binding moiety.

### Claim 3 (depends on 2)

The targeting gene delivery vehicle complex of claim 2, wherein the immunoglobulin binding moiety is capable of binding to a constant region of an immunoglobulin.

### Claim 4 (depends on 3)

The targeting gene delivery vehicle complex of claim 3, wherein the immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

### Claim 5 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the first member of the specific binding pair comprises a fusion protein.

### Claim 6 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the recombinant gene of interest encodes a protein.

### Claim 7 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the recombinant gene of interest comprises a suicide gene.

### Claim 8 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the recombinant gene of interest comprises an antisense nucleic acid.

### Claim 9 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the second member of the specific binding pair comprises an immunoglobulin.

### Claim 10 (depends on 1)

The targeting gene delivery vehicle complex of claim 1, wherein the targeting moiety comprises an antibody or a fragment or a derivative thereof

### Claim 11

A kit of parts for delivering genetic material to a target cell, comprising:
a gene delivery vehicle, said gene delivery vehicle comprising:
a retrovirus comprising an expressible nucleic acid molecule encoding a recombinant gene of interest, and
a first member of a specific binding pair, wherein said first member of the specific binding pair is recombinantly expressed on the exterior of the retrovirus; and
a bispecific conjugate for coupling to said first member of the specific binding pair, said bispecific conjugate comprising a second member of the specific binding pair covalently coupled to a targeting moiety, said targeting moiety capable of binding to a target molecule associated with a surface of the target cell.

### Claim 12 (depends on 11)

The kit of parts of claim 11, wherein the first member of a specific binding pair comprises an immunoglobulin binding moiety.

### Claim 13 (depends on 12)

The kit of parts of claim 12, wherein the immunoglobulin binding moiety is capable of binding to a constant region of an immunoglobulin.

### Claim 14 (depends on 13)

The kit of parts of claim 13, wherein the immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

### Claim 15 (depends on 11)

The kit of parts of claim 11, wherein the first member of the specific binding pair comprises a fusion protein.

### Claim 16 (depends on 11)

The kit of parts of claim 11, wherein the recombinant gene of interest encodes a protein.

### Claim 17 (depends on 11)

The kit of parts of claim 11, wherein the recombinant gene of interest comprises a suicide gene.

### Claim 18 (depends on 11)

The kit of parts of claim 11, wherein the recombinant gene of interest comprises an antisense nucleic acid.

### Claim 19 (depends on 11)

The kit of parts of claim 11, wherein the second member of the specific binding pair comprises an immunoglobulin.

### Claim 20 (depends on 11)

The kit of parts of claim 11, wherein the targeting moiety comprises an antibody or a fragment or a derivative thereof.

### Claim 21 (depends on 11)

The kit of parts of claim 11, wherein the first and second member of said specific binding pair comprise streptavidin and biotin, or avidin and biotin.

### Claim 22 (depends on 11)

The kit of parts of claim 11, wherein the first and second member of said specific binding pair are peptides forming three-dimensional structures in solution.

### Claim 23 (depends on 11)

The kit of parts of claim 11, wherein the targeting moiety comprises a ligand and wherein the target molecule is a receptor for the ligand.

### Claim 24 (depends on 1)

A method for delivering genetic material to a target cell in vitro, comprising
delivering the gene delivery vehicle complex of claim 1 to the target cell in vitro.

### Claim 25 (depends on 24)

The method of claim 24, wherein the first member of a specific binding pair comprises an immunoglobulin binding moiety.

### Claim 26 (depends on 25)

The method of claim 25, wherein the immunoglobulin binding moiety is capable of binding to a constant region of an immunoglobulin.

### Claim 27 (depends on 26)

The method of claim 26, wherein the immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

### Claim 28 (depends on 24)

The method of claim 24, wherein the first member of the specific binding pair comprises a fusion protein.

### Claim 29 (depends on 24)

The method of claim 24, wherein the recombinant gene of interest encodes a protein.

### Claim 30 (depends on 24)

The method of claim 24, wherein the targeting moiety comprises an antibody or a fragment or a derivative thereof.

### Claim 31 (depends on 24)

The method of claim 24, wherein the first and second member of said specific binding pair comprise streptavidin and biotin or avidin and biotin.

### Claim 32 (depends on 24)

The method of claim 24, wherein the first and second member of said specific binding pair are peptides forming three-dimensional structures in solution.

### Claim 33 (depends on 24)

The method of claim 24, wherein the targeting moiety comprises a ligand and wherein the target molecule is a receptor for the ligand.

### Claim 34

A targeting gene delivery vehicle complex, the targeting gene delivery vehicle complex comprising:
a gene delivery vehicle coupled to a bispecific conjugate;
wherein the gene delivery vehicle comprises:
a retrovirus comprising an expressible nucleic acid molecule encoding a recombinant gene of interest; and
a first member of a specific binding pair, wherein the first member of the specific binding pair is recombinantly expressed and present on or in the exterior of the retrovirus; and
wherein said bispecific conjugate comprises a second member of said specific binding pair covalently coupled to a targeting moiety capable of binding to a target molecule associated with the surface of a target cell.
